Gilead Sciences (GILD) finished the most recent trading day at $110.17, reflecting a +1.75% increase compared to the previous day. This performance exceeded the S&P 500’s 0.06% rise for the day. Meanwhile, the Dow saw a 0.41% increase, while the Nasdaq, which is focused on technology stocks, experienced a decline of 0.39%.
Prior to today, the stock of the HIV and hepatitis C medication company had increased by 1.97% over the last month. During the same period, the Healthcare sector declined by 1.83%, whereas the S&P 500 rose by 5.88%.
Support kami, ada hadiah spesial untuk anda.
Klik di sini: https://indonesiacrowd.com/support-bonus/
The financial sector will be closely monitoring the earnings results of Gilead Sciences in its next report. It is expected that the company will announce an EPS of $1.96, reflecting a 2.49% decrease from the same period in the prior year. In addition, our latest collective forecast predicts revenue of $6.96 billion, showing a 0.09% increase compared to the same quarter last year.
The Zacks Consensus Estimates predict earnings of $7.91 per share and revenue of $28.68 billion for the entire year, showing increases of +71.21% and decreases of -0.24% compared to the previous year.
Furthermore, investors should monitor any recent changes in analyst predictions for Gilead Sciences. These updates often indicate the shifting dynamics of short-term market conditions. Therefore, upward revisions in estimates can be seen as a positive indicator for the company’s future performance.
Support us — there's a special gift for you.
Click here: https://indonesiacrowd.com/support-bonus/
Our study indicates that these estimate adjustments are closely linked to short-term stock movements. Traders can benefit from this by utilizing the Zacks Rank. This approach takes into account these changes and offers an easy-to-use, practical rating system.
The Zacks Rank system, which spans from #1 (Strong Buy) to #5 (Strong Sell), has a proven track record of exceeding expectations, as verified by independent audits, with #1 ranked stocks averaging an annual return of +25% since 1988. The Zacks Consensus EPS forecast has decreased by 0.11% over the last month. Gilead Sciences currently holds a Zacks Rank of #3 (Hold).
From a valuation perspective, Gilead Sciences has a Forward P/E ratio of 13.69. The average Forward P/E for its industry stands at 17.79, suggesting that Gilead Sciences may be available at a lower price relative to its peers.
It’s also important to mention that GILD currently has a PEG ratio of 0.7. The PEG ratio is comparable to the commonly used P/E ratio, but this measure also considers the company’s anticipated earnings growth rate. The Medical – Biomedical and Genetics sector had an average PEG ratio of 1.47 at yesterday’s closing price.
The Healthcare – Biomedical and Genetics sector falls under the broader Medical industry. Currently, this sector holds a Zacks Industry Rank of 95, placing it within the top 39% among more than 250 industries.
The Zacks Industry Rank evaluates the performance of our various industry groups by calculating the average Zacks Rank of the stocks in each group. According to our analysis, industries ranked in the top 50% tend to outperform those in the lower half by a ratio of 2 to 1.
To track GILD in the upcoming trading sessions, make sure to use .
This piece was first released on Zacks Investment Research ().
